高危上尿路尿路上皮癌术前化疗的疗效
这项国际观察性研究纳入2005至2017年间接受术前化疗后行根治性肾输尿管切除术的高危上尿路尿路上皮癌患者267例,评估病理完全缓解(pT0N0/X)率和降期(≤pT1N0/X)率及其对生存的影响。结果显示病理完全缓解率为10.1%,降期率为44.9%,病理降期是复发-free生存、癌症特异性生存和总生存的最强预后因素。
要点
- 术前化疗后病理降期率为44.9%,完全缓解率为10.1%。
- 病理降期是生存的最强预后因素(HR 0.2-0.40)。
- 不同化疗方案在病理缓解上无统计学差异。
核心结论
- 术前化疗后的病理降期是根治性肾输尿管切除术后强有力的预后因素,与生存改善相关。
研究设计与样本
- 国际观察性研究,纳入2005至2017年间接受术前化疗和根治性肾输尿管切除术的高危上尿路尿路上皮癌患者267例。
主要发现
- 总体病理完全缓解率为10.1%,病理降期率为44.9%。
- 病理降期对无复发生存(HR 0.2,p<0.001)、癌症特异性生存(HR 0.19,p<0.001)和总生存(HR 0.40,p<0.001)是最强预后因素。
- 多变量分析中,吉西他滨联合顺铂或卡铂与MVAC方案在病理完全缓解和降期方面无统计学差异。
- 化疗周期数对病理缓解无影响。
临床怎么用
- 术前化疗后病理降期可作为根治性肾输尿管切除术后生存的预后指标。
局限性
- 需要设计良好的前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The impact of preoperative chemotherapy in patients with upper urinary tract urothelial carcinoma remains poorly investigated. We assessed the rates of pathological complete response (pT0N0/X) and downstaging (pT1N0/X or less) at radical nephroureterectomy after preoperative chemotherapy and evaluated their impact on survival. MATERIALS AND METHODS: This was an international observational study of patients who underwent preoperative chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma between 2005 and 2017. Multiple imputation of chained equations was applied to account for missing values. Logistic regression analyses were performed to identify predictors of pathological response. Cox proportional hazard regression models were used to estimate recurrence-free survival, cancer specific survival and overall survival. RESULTS: A total of 267 patients met our inclusion criteria. Among included patients 82 (31%) received methotrexate, vinblastine, doxorubicin and cisplatin; 123 (46%) gemcitabine and cisplatin; 25 (9%) gemcitabine and carboplatin; and 32 (12%) other regimens. The overall rates of pathological complete response and pathological downstaging were 10.1% and 44.9%, respectively. On multivariable analysis the use of gemcitabine and cisplatin, and gemcitabine and carboplatin was not statistically different from methotrexate, vinblastine, doxorubicin and cisplatin in achieving pathological complete response and pathological downstaging, respectively. The number of administered cycles did not appear to have an effect on pathological responses. Pathological downstaging was the strongest prognostic factor for recurrence-free survival (HR 0.2, p <0.001), cancer specific survival (HR 0.19, p <0.001) and overall survival (HR 0.40, p <0.001). CONCLUSIONS: Pathological downstaging after preoperative chemotherapy is a robust prognostic factor at radical nephroureterectomy and is associated with improved survival outcomes. Although preoperative chemotherapy appears to be effective, well designed prospective studies are still needed.
引用
- Foerster B, Abufaraj M, Petros F, et al. Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. J Urol. 2020. PMID: 31898919. doi:10.1097/JU.0000000000000737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。